Literature DB >> 18704622

Molecular and clinical investigations in patients with low-renin hypertension.

Isla S Mackenzie1, Morris J Brown.   

Abstract

Interactions between the renin-angiotensin-aldosterone system and other mechanisms determining sodium balance are important in the pathophysiology of hypertension. Low-renin hypertension is a common type of resistant hypertension and is often associated with increased sodium retention. The importance of investigation, factors determining renin and aldosterone levels, and drug therapies in low-renin hypertension are reviewed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18704622     DOI: 10.1007/s10157-008-0071-4

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  26 in total

1.  Calcium-channel blockade can mask the diagnosis of Conn's syndrome.

Authors:  M J Brown; R V Hopper
Journal:  Postgrad Med J       Date:  1999-04       Impact factor: 2.401

2.  Double-blind, placebo-controlled crossover comparison of five classes of antihypertensive drugs.

Authors:  Alison J Deary; Anne L Schumann; Helen Murfet; Stephen F Haydock; Roger S-Y Foo; Morris J Brown
Journal:  J Hypertens       Date:  2002-04       Impact factor: 4.844

3.  Clinical implications of primary aldosteronism with resistant hypertension.

Authors:  E L Bravo; F M Fouad-Tarazi; R C Tarazi; M Pohl; R W Gifford; D G Vidt
Journal:  Hypertension       Date:  1988-02       Impact factor: 10.190

4.  Optimisation of antihypertensive treatment by crossover rotation of four major classes.

Authors:  J E Dickerson; A D Hingorani; M J Ashby; C R Palmer; M J Brown
Journal:  Lancet       Date:  1999-06-12       Impact factor: 79.321

5.  Acute calcium entry blockade inhibits the blood pressure but not the hormonal responses to angiotensin II.

Authors:  J Staessen; R Fagard; P Hespel; P Lijnen; E Moerman; A Amery
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

6.  Blockade of T-type voltage-dependent Ca2+ channels by benidipine, a dihydropyridine calcium channel blocker, inhibits aldosterone production in human adrenocortical cell line NCI-H295R.

Authors:  Osamu Akizuki; Atsushi Inayoshi; Tetsuya Kitayama; Kozo Yao; Shiro Shirakura; Katsutoshi Sasaki; Hideaki Kusaka; Masahiro Matsubara
Journal:  Eur J Pharmacol       Date:  2008-02-12       Impact factor: 4.432

7.  Expression of the epithelial Na(+) channel and other components of an aldosterone response pathway in human adrenocortical cells.

Authors:  Timothy J Burton; Georgina Cope; Jing Wang; Joalice C Sim; Elena A B Azizan; Kevin M O'Shaughnessy; Morris J Brown
Journal:  Eur J Pharmacol       Date:  2009-04-14       Impact factor: 4.432

8.  Therapeutic effect of calcium channel blockade in primary aldosteronism.

Authors:  J L Nadler; W Hsueh; R Horton
Journal:  J Clin Endocrinol Metab       Date:  1985-05       Impact factor: 5.958

9.  Effect of nifedipine on blood pressure and adrenocortical responses to trophic stimuli in humans.

Authors:  J A Millar; A D Struthers; G H Beastall; J L Reid
Journal:  J Cardiovasc Pharmacol       Date:  1982       Impact factor: 3.105

10.  The spironolactone, amiloride, losartan, and thiazide (SALT) double-blind crossover trial in patients with low-renin hypertension and elevated aldosterone-renin ratio.

Authors:  Susan J Hood; Kevin P Taylor; Michael J Ashby; Morris J Brown
Journal:  Circulation       Date:  2007-07-02       Impact factor: 29.690

View more
  4 in total

Review 1.  Primary aldosteronism: A contrarian view.

Authors:  Norman M Kaplan
Journal:  Rev Endocr Metab Disord       Date:  2011-03       Impact factor: 6.514

Review 2.  The relevance of the Renin-Angiotensin system in the development of drugs to combat preeclampsia.

Authors:  Norikazu Ueki; Satoru Takeda; Daisuke Koya; Keizo Kanasaki
Journal:  Int J Endocrinol       Date:  2015-04-27       Impact factor: 3.257

3.  Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trial.

Authors:  Morris J Brown; Bryan Williams; Steve V Morant; David J Webb; Mark J Caulfield; J Kennedy Cruickshank; Ian Ford; Gordon McInnes; Peter Sever; Jackie Salsbury; Isla S Mackenzie; Sandosh Padmanabhan; Thomas M MacDonald
Journal:  Lancet Diabetes Endocrinol       Date:  2015-10-18       Impact factor: 32.069

Review 4.  The importance of the epithelial sodium channel in determining salt sensitivity in people of African origin.

Authors:  Erika Jones; Brian Rayner
Journal:  Pediatr Nephrol       Date:  2020-01-02       Impact factor: 3.714

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.